Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 2
1989 2
1991 1
1993 1
1995 2
1996 3
1998 2
1999 1
2000 4
2001 5
2002 2
2003 6
2004 8
2005 1
2006 6
2007 5
2008 2
2009 2
2010 3
2011 2
2012 1
2013 4
2014 8
2015 3
2016 4
2017 5
2018 3
2019 12
2020 23
2021 24
2022 16
Text availability
Article attribute
Article type
Publication date

Search Results

149 results
Results by year
Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. Among authors: leppert d. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Serum neurofilament light as a biomarker in progressive multiple sclerosis.
Kapoor R, Smith KE, Allegretta M, Arnold DL, Carroll W, Comabella M, Furlan R, Harp C, Kuhle J, Leppert D, Plavina T, Sellebjerg F, Sincock C, Teunissen CE, Topalli I, von Raison F, Walker E, Fox RJ. Kapoor R, et al. Among authors: leppert d. Neurology. 2020 Sep 8;95(10):436-444. doi: 10.1212/WNL.0000000000010346. Epub 2020 Jul 16. Neurology. 2020. PMID: 32675076 Free PMC article. Review.
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Disanto G, et al. Among authors: leppert d. Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954. Ann Neurol. 2017. PMID: 28512753 Free PMC article.
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Benkert P, et al. Among authors: leppert d. Lancet Neurol. 2022 Mar;21(3):246-257. doi: 10.1016/S1474-4422(22)00009-6. Lancet Neurol. 2022. PMID: 35182510
Neurofilaments: neurobiological foundations for biomarker applications.
Gafson AR, Barthélemy NR, Bomont P, Carare RO, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA, Weller RO, Zetterberg H, Matthews PM. Gafson AR, et al. Among authors: leppert d. Brain. 2020 Jul 1;143(7):1975-1998. doi: 10.1093/brain/awaa098. Brain. 2020. PMID: 32408345 Free PMC article. Review.
Factors influencing serum neurofilament light chain levels in normal aging.
Koini M, Pirpamer L, Hofer E, Buchmann A, Pinter D, Ropele S, Enzinger C, Benkert P, Leppert D, Kuhle J, Schmidt R, Khalil M. Koini M, et al. Among authors: leppert d. Aging (Albany NY). 2021 Dec 18;13(24):25729-25738. doi: 10.18632/aging.203790. Epub 2021 Dec 18. Aging (Albany NY). 2021. PMID: 34923481 Free PMC article.
Matrix metalloproteinases in immunity.
Goetzl EJ, Banda MJ, Leppert D. Goetzl EJ, et al. Among authors: leppert d. J Immunol. 1996 Jan 1;156(1):1-4. J Immunol. 1996. PMID: 8598448 Review.
149 results